Review Article

鞘内给药治疗实体癌轻脑膜转移的有效性和安全性综述

卷 31, 期 19, 2024

发表于: 14 June, 2023

页: [2732 - 2750] 页: 19

弟呕挨: 10.2174/0929867330666230508142657

价格: $65

conference banner
摘要

轻脑膜病(LMD)是一种罕见且致命的表现,可能发生在实体肿瘤和血液系统恶性肿瘤的晚期。随着诊断技术的进步,发现和确认LMD的存在有所增加。尽管其最佳治疗方法仍然是一个挑战,但使用鞘内途径递送新疗法现在被认为是一种有前途的药物递送策略,以补充放射和系统为基础的治疗。尽管甲氨蝶呤、阿糖胞苷和硫替巴在治疗LMD方面有着悠久的历史,但其他药物也被证明是有益的。在这篇文章中,我们回顾了通过鞘内途径给药治疗实体瘤的新药物的效果。截至2021年9月底,我们检索了PubMed、Scopus和Google Scholar数据库,检索关键词为:“柔脑膜疾病”、“柔脑膜癌”、“柔脑膜转移”、“实体瘤”、“实体癌”和“鞘内”。我们的文献发现发现,大多数关于继发于实体癌的LMD的研究都是“病例报告”,迄今为止很少进行临床试验。经鞘内给药的单药(单药治疗)或联合药物治疗,特别是转移性乳腺癌和肺癌,已被证明可以改善患者的症状和总体寿命,同时显示出低且可接受的副作用发生率。然而,这些药物的有效性和安全性的判断/结论仍需要进一步的临床评价。

关键词: 肉脑膜病,柔脑膜癌,实体瘤,鞘内瘤,LMD,恶性肿瘤。

[1]
Byun, Y.H.; Gwak, H.S.; Kwon, J.W.; Kim, K.G.; Shin, S.H.; Lee, S.H.; Yoo, H. A novel implantable cerebrospinal fluid reservoir: A pilot study. J. Korean Neurosurg. Soc., 2018, 61(5), 640-644.
[http://dx.doi.org/10.3340/jkns.2018.0098] [PMID: 30196661]
[2]
Thakkar, J.P.; Kumthekar, P.; Dixit, K.S.; Stupp, R.; Lukas, R.V. Leptomeningeal metastasis from solid tumors. J. Neurol. Sci., 2020, 411, 116706.
[http://dx.doi.org/10.1016/j.jns.2020.116706] [PMID: 32007755]
[3]
Alexis Demopoulos, M.; Paul Brown, M. Treatment of leptomeningeal metastases (carcinomatous meningitis). 2018.
[4]
Carausu, M.; Carton, M.; Darlix, A.; Pasquier, D.; Leheurteur, M.; Debled, M.; Mouret-Reynier, M.A.; Goncalves, A.; Dalenc, F.; Verret, B.; Campone, M.; Augereau, P.; Ferrero, J.M.; Levy, C.; Fumet, J.D.; Lefeuvre-Plesse, C.; Petit, T.; Uwer, L.; Jouannaud, C.; Larrouquere, L.; Chevrot, M.; Courtinard, C.; Cabel, L. Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database. ESMO Open, 2021, 6(3), 100150.
[http://dx.doi.org/10.1016/j.esmoop.2021.100150] [PMID: 33984675]
[5]
Nguyen, T.K.; Nguyen, E.K.; Soliman, H. An overview of leptomeningeal disease. Ann. Palliat. Med., 2020.
[PMID: 32921068]
[6]
Le Rhun, E.; Preusser, M.; van den Bent, M.; Andratschke, N.; Weller, M. How we treat patients with leptomeningeal metastases. ESMO Open, 2019, 4(S2), e000507.
[http://dx.doi.org/10.1136/esmoopen-2019-000507] [PMID: 31231573]
[7]
Clarke, J.L.; Perez, H.R.; Jacks, L.M.; Panageas, K.S.; DeAngelis, L.M. Leptomeningeal metastases in the MRI era. Neurology, 2010, 74(18), 1449-1454.
[http://dx.doi.org/10.1212/WNL.0b013e3181dc1a69] [PMID: 20439847]
[8]
Clarke, J.L. Leptomeningeal metastasis from systemic cancer. Continuum (Minneap. Minn.), 2012, 18(2), 328-342.
[http://dx.doi.org/10.1212/01.CON.0000413661.58045.e7] [PMID: 22810130]
[9]
White, M.D.; Klein, R.H.; Shaw, B.; Kim, A.; Subramanian, M.; Mora, J.L. Detection of leptomeningeal disease using cell-free DNA from cerebrospinal fluid. JAMA Netw Open, 2021, 4(8), e2120040.
[http://dx.doi.org/10.1001/jamanetworkopen.2021.20040]
[10]
Li, Y.; Pan, W.; Connolly, I.D.; Reddy, S.; Nagpal, S.; Quake, S. Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. J. Neurooncol., 2016, 128, 93-100.
[http://dx.doi.org/10.1007/s11060-016-2081-5]
[11]
Pellerino, A.; Bertero, L.; Rudà, R.; Soffietti, R. Neoplastic meningitis in solid tumors: From diagnosis to personalized treatments. Ther. Adv. Neurol. Disord., 2018, 11
[http://dx.doi.org/10.1177/1756286418759618] [PMID: 29535794]
[12]
Thomas, K.H.; Ramirez, R.A. Leptomeningeal disease and the evolving role of molecular targeted therapy and immunotherapy. Ochsner J., 2017, 17(4), 362-378.
[PMID: 29230121]
[13]
de Oca Delgado, M.M.; Cacho, D.B.; Santos, Z.J.; Guerrero, J.V.; López, M.M.S.; Castro, M.E.; Méndez-Padilla, A.J.; Mejía, P.S.; Reyes, M.I.; Gutiérrez, A.A.; González, A.A. The comparative treatment of intraventricular chemotherapy by Ommaya reservoir vs. lumbar puncture in patients with leptomeningeal carcinomatosis. Front. Oncol., 2018, 8, 509.
[http://dx.doi.org/10.3389/fonc.2018.00509] [PMID: 30524956]
[14]
Rueda, D.A.; Olmos, H.D.; Viciana, G.R.; Torres, S.E. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis. Clin. Transl. Oncol., 2005, 7(6), 232-238.
[15]
Vergoulidou, M. Leptomeningeal carcinomatosis in gastric cancer: A therapeutical challenge. Biomark. Insights, 2017, 12
[http://dx.doi.org/10.1177/1177271917695237] [PMID: 28469397]
[16]
Yamasaki, T.; Fukui, H.; Sei, H.; Hara, K.; Eda, H.; Kondo, T.; Toyoshima, F.; Kono, T.; Tozawa, K.; Ikehara, H.; Tomita, T.; Oshima, T.; Watari, J.; Miwa, H. Efficacy of intrathecal MTX/Ara-C combined with systemic chemotherapy in a gastric cancer patient with meningeal carcinomatosis. Intern. Med., 2016, 55(6), 609-611.
[http://dx.doi.org/10.2169/internalmedicine.55.5129] [PMID: 26984076]
[17]
Yamakawa, H.; Ariga, H.; Enomoto, A.; Netsu, S.; Suzuki, Y.; Konno, R. Meningeal dissemination from an ovarian carcinoma with effective response to intrathecal chemotherapy. Int. J. Clin. Oncol., 2009, 14(5), 447-451.
[http://dx.doi.org/10.1007/s10147-008-0846-3] [PMID: 19856055]
[18]
Oh, S.Y.; Lee, S.J.; Lee, J.; Lee, S.; Kim, S.H.; Kwon, H.C.; Lee, G.W.; Kang, J.H.; Hwang, I.G.; Jang, J.S.; Lim, H.Y.; Park, Y.S.; Kang, W.K.; Kim, H.J. Gastric leptomeningeal carcinomatosis: Multi-center retrospective analysis of 54 cases. World J. Gastroenterol., 2009, 15(40), 5086-5090.
[http://dx.doi.org/10.3748/wjg.15.5086] [PMID: 19860003]
[19]
Huppert, L.A.; Melisko, M.E.; Glastonbury, C.M.; Khanafshar, E.; Daud, A.I. Treatment of metastatic melanoma with leptomeningeal disease using intrathecal immunotherapy. JCO Oncol. Pract., 2020, 16(11), 757-759.
[http://dx.doi.org/10.1200/OP.20.00146] [PMID: 32603255]
[20]
Glitza, I.C.; Rohlfs, M.L.; Iqbal, M.; Richard, J.; Burton, E.; Duncan, S.; Brown, C.; Anderson, J.; Hwu, P.; Hwu, W-J.; Wong, M.; Yee, C.; Patel, S.; Woodman, S.; Amaria, R.; Diab, A.; Tawbi, H.; Davies, M. A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD). Ann. Oncol., 2018, 29, viii464.
[http://dx.doi.org/10.1093/annonc/mdy289.057]
[21]
John, I.; Foster, A.P.; Haymaker, C.L.; Bassett, R.L.; Lee, J.J.; Rohlfs, M.L. Intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). J. Clin. Oncol., 2021, 39(15)
[http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.9519]
[22]
Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gümüş, M.; Mazières, J.; Hermes, B.; Çay Şenler, F.; Csőszi, T.; Fülöp, A.; Rodríguez-Cid, J.; Wilson, J.; Sugawara, S.; Kato, T.; Lee, K.H.; Cheng, Y.; Novello, S.; Halmos, B.; Li, X.; Lubiniecki, G.M.; Piperdi, B.; Kowalski, D.M. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N. Engl. J. Med., 2018, 379(21), 2040-2051.
[http://dx.doi.org/10.1056/NEJMoa1810865] [PMID: 30280635]
[23]
Khoja, L.; Butler, M.O.; Kang, S.P.; Ebbinghaus, S.; Joshua, A.M. Pembrolizumab. J. Immunother. Cancer, 2015, 3(1), 36.
[http://dx.doi.org/10.1186/s40425-015-0078-9] [PMID: 26288737]
[24]
Schmid, P.; Cortes, J.; Pusztai, L.; McArthur, H.; Kümmel, S.; Bergh, J.; Denkert, C.; Park, Y.H.; Hui, R.; Harbeck, N.; Takahashi, M.; Foukakis, T.; Fasching, P.A.; Cardoso, F.; Untch, M.; Jia, L.; Karantza, V.; Zhao, J.; Aktan, G.; Dent, R.; O’Shaughnessy, J. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med., 2020, 382(9), 810-821.
[http://dx.doi.org/10.1056/NEJMoa1910549] [PMID: 32101663]
[25]
Naidoo, J.; Schreck, K.; Fu, W.; Hu, C.; Connolly, R.; Santa-Maria, C. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. J. Immunother. Cancer, 2020, 9(8), e002473.
[26]
Brastianos, P.K.; Lee, E.Q.; Cohen, J.V.; Tolaney, S.M.; Lin, N.U.; Wang, N.; Chukwueke, U.; White, M.D.; Nayyar, N.; Kim, A.; Alvarez-Breckenridge, C.; Krop, I.; Mahar, M.K.; Bertalan, M.S.; Shaw, B.; Mora, J.L.; Goss, N.; Subramanian, M.; Nayak, L.; Dietrich, J.; Forst, D.A.; Nahed, B.V.; Batchelor, T.T.; Shih, H.A.; Gerstner, E.R.; Moy, B.; Lawrence, D.; Giobbie-Hurder, A.; Carter, S.L.; Oh, K.; Cahill, D.P.; Sullivan, R.J. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat. Med., 2020, 26(8), 1280-1284.
[http://dx.doi.org/10.1038/s41591-020-0918-0] [PMID: 32483359]
[27]
Ensign, S.P.F.; Yancey, E.; Anderson, K.S.; Mrugala, M.M. Safety and feasibility of intrathecal pembrolizumab infusion in refractory triple negative breast cancer with leptomeningeal disease: A case report. Current Problems in Cancer: Case Reports, 2021, 4, 100103.
[http://dx.doi.org/10.1016/j.cpccr.2021.100103]
[28]
Boland, W.K.; Bebb, G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin. Biol. Ther., 2009, 9(9), 1199-1206.
[http://dx.doi.org/10.1517/14712590903110709] [PMID: 19624281]
[29]
Jiao, S.; Ju, Y.; Wang, J.; Sun, S. Nimotuzumab treatment and outcome analysis in patients with leptomeningeal metastasis from nonsmall cell lung cancer. J. Cancer Res. Ther., 2016, 12(S7), 181.
[http://dx.doi.org/10.4103/0973-1482.200596] [PMID: 28230014]
[30]
Figura, N.B.; Rizk, V.T.; Armaghani, A.J.; Arrington, J.A.; Etame, A.B.; Han, H.S.; Czerniecki, B.J.; Forsyth, P.A.; Ahmed, K.A. Breast leptomeningeal disease: A review of current practices and updates on management. Breast Cancer Res. Treat., 2019, 177(2), 277-294.
[http://dx.doi.org/10.1007/s10549-019-05317-6] [PMID: 31209686]
[31]
McKeage, K.; Perry, C.M. Trastuzumab. Drugs, 2002, 62(1), 209-243.
[http://dx.doi.org/10.2165/00003495-200262010-00008] [PMID: 11790161]
[32]
Keefe, D.L. Trastuzumab-associated cardiotoxicity. Cancer, 2002, 95(7), 1592-1600.
[http://dx.doi.org/10.1002/cncr.10854] [PMID: 12237930]
[33]
Curigliano, G; Mueller, V; Borges, V; Hamilton, E; Hurvitz, S; Loi, S Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis. Ann Oncol, 2022, 33(3), 321-329.
[34]
Ferrario, C.; Davidson, A.; Bouganim, N.; Aloyz, R.; Panasci, L.C. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann. Oncol., 2009, 20(4), 792-795.
[http://dx.doi.org/10.1093/annonc/mdp019] [PMID: 19223574]
[35]
Perissinotti, A.J.; Reeves, D.J. Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann. Pharmacother., 2010, 44(10), 1633-1640.
[http://dx.doi.org/10.1345/aph.1P197] [PMID: 20807868]
[36]
Figura, N.B.; Rizk, V.T.; Mohammadi, H.; Evernden, B.; Mokhtari, S.; Yu, H.M.; Robinson, T.J.; Etame, A.B.; Tran, N.D.; Liu, J.; Washington, I.; Diaz, R.; Czerniecki, B.J.; Soliman, H.; Han, H.S.; Sahebjam, S.; Forsyth, P.A.; Ahmed, K.A. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res. Treat., 2019, 175(3), 781-788.
[http://dx.doi.org/10.1007/s10549-019-05170-7] [PMID: 30859348]
[37]
Figura, N.B.; Long, W.; Yu, M.; Robinson, T.J.; Mokhtari, S.; Etame, A.B.; Tran, N.D.; Diaz, R.; Soliman, H.; Han, H.S.; Sahebjam, S.; Forsyth, P.A.; Ahmed, K.A. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: A single institution experience. Breast Cancer Res. Treat., 2018, 169(2), 391-396.
[http://dx.doi.org/10.1007/s10549-018-4684-3] [PMID: 29392582]
[38]
Zagouri, F.; Sergentanis, T.N.; Bartsch, R.; Berghoff, A.S.; Chrysikos, D.; de Azambuja, E.; Dimopoulos, M.A.; Preusser, M. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: A systematic review and pooled analysis. Breast Cancer Res. Treat., 2013, 139(1), 13-22.
[http://dx.doi.org/10.1007/s10549-013-2525-y] [PMID: 23588955]
[39]
Lu, N.T.; Raizer, J.; Gabor, E.P.; Liu, N.M.; Vu, J.Q.; Slamon, D.J.; Barstis, J.L. Intrathecal trastuzumab: Immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient. J. Immunother. Cancer, 2015, 3(1), 41.
[http://dx.doi.org/10.1186/s40425-015-0084-y] [PMID: 26380087]
[40]
Stemmler, H.J.; Schmitt, M.; Harbeck, N.; Willems, A.; Bernhard, H.; Lässig, D.; Schoenberg, S.; Heinemann, V. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol. Rep., 2006, 15(5), 1373-1377.
[PMID: 16596213]
[41]
Lombardi, G.; Zustovich, F.; Farina, P.; Della Puppa, A.; Manara, R.; Cecchin, D.; Brunello, A.; Cappetta, A.; Zagonel, V. Neoplastic meningitis from solid tumors: New diagnostic and therapeutic approaches. Oncologist, 2011, 16(8), 1175-1188.
[http://dx.doi.org/10.1634/theoncologist.2011-0101] [PMID: 21795431]
[42]
Carmichael, J.; Possinger, K.; Phillip, P.; Beykirch, M.; Kerr, H.; Walling, J.; Harris, A.L. Advanced breast cancer: A phase II trial with gemcitabine. J. Clin. Oncol., 1995, 13(11), 2731-2736.
[http://dx.doi.org/10.1200/JCO.1995.13.11.2731] [PMID: 7595731]
[43]
Von Hoff, D.D.; Ervin, T.; Arena, F.P.; Chiorean, E.G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S.A.; Ma, W.W.; Saleh, M.N.; Harris, M.; Reni, M.; Dowden, S.; Laheru, D.; Bahary, N.; Ramanathan, R.K.; Tabernero, J.; Hidalgo, M.; Goldstein, D.; Van Cutsem, E.; Wei, X.; Iglesias, J.; Renschler, M.F. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med., 2013, 369(18), 1691-1703.
[http://dx.doi.org/10.1056/NEJMoa1304369] [PMID: 24131140]
[44]
Chen, Y.M.; Chen, M.C.; Tsai, C.M.; Perng, R.P. Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis—a case report. Lung Cancer, 2003, 40(1), 99-101.
[http://dx.doi.org/10.1016/S0169-5002(02)00504-4] [PMID: 12660014]
[45]
Bernardi, R.J.; Bomgaars, L.; Fox, E.; Balis, F.M.; Egorin, M.J.; Lagattuta, T.F.; Aikin, A.; Whitcomb, P.; Renbarger, J.; Lieberman, F.S.; Berg, S.L.; Blaney, S.M. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother. Pharmacol., 2008, 62(2), 355-361.
[http://dx.doi.org/10.1007/s00280-007-0601-x] [PMID: 17909804]
[46]
Miao, Q.; Zheng, X.; Zhang, L.; Jiang, K.; Wu, B.; Lin, G. Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis. Ann. Palliat. Med., 2020, 9(6), 4233-4245.
[http://dx.doi.org/10.21037/apm-20-2086] [PMID: 33302683]
[47]
Ma, Y.; Liu, H.; Zhang, M.; Liu, B.; Ding, Q.; Zhang, L. Successful treatment using targeted therapy, radiotherapy, and intrathecal chemotherapy in a patient with leptomeningeal metastasis with an epidermal growth factor receptor exon 20 insertion mutation: A case report. Ann. Palliat. Med., 2021, 11(4), 1533-1541.
[PMID: 34263612]
[48]
Fan, C.; Zhao, Q.; Li, L.; Shen, W.; Du, Y.; Teng, C.; Gao, F.; Song, X.; Jiang, Q.; Huang, D.; Jin, Y.; Lv, Y.; Wei, L.; Shi, T.; Zhao, X.; Gao, N.; Jiang, Z.; Xin, T. Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-Mutant NSCLC—a prospective, open-label, single-arm phase 1/2 clinical trial (unique identifier: ChiCTR1800016615). J. Thorac. Oncol., 2021, 16(8), 1359-1368.
[http://dx.doi.org/10.1016/j.jtho.2021.04.018] [PMID: 33989780]
[49]
Li, H.; Lin, Y.; Yu, T.; Xie, Y.; Feng, J.; Huang, M.; Guo, A.; Liu, X.; Yin, Z. Treatment response to intrathecal chemotherapy with pemetrexed via an Ommaya reservoir in EGFR-mutated leptomeningeal metastases from non-small cell lung cancer: A case report. Ann. Palliat. Med., 2020, 9(4), 2341-2346.
[http://dx.doi.org/10.21037/apm-19-521] [PMID: 32648459]
[50]
Pan, Z.; Yang, G.; Cui, J.; Li, W.; Li, Y.; Gao, P.; Jiang, T.; Sun, Y.; Dong, L.; Song, Y.; Zhao, G. A pilot phase 1 study of intrathecal pemetrexed for refractory leptomeningeal metastases from non-small-cell lung cancer. Front. Oncol., 2019, 9, 838.
[http://dx.doi.org/10.3389/fonc.2019.00838] [PMID: 31544065]
[51]
Pan, Z.; Yang, G.; He, H.; Cui, J.; Li, W.; Yuan, T.; Chen, K.; Jiang, T.; Gao, P.; Sun, Y.; Cong, X.; Li, Z.; Wang, Y.; Pang, X.; Song, Y.; Zhao, G. Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: A phase I/II study. Ther. Adv. Med. Oncol., 2020, 12
[http://dx.doi.org/10.1177/1758835920937953] [PMID: 32733606]
[52]
Mazur, L.; Opydo-Chanek, M.; Stojak, M.; Wojcieszek, K. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials. Anticancer Res., 2012, 32(7), 2783-2789.
[PMID: 22753738]
[53]
Blaney, S.M.; Balis, F.M.; Berg, S.; Arndt, C.A.S.; Heideman, R.; Geyer, J.R.; Packer, R.; Adamson, P.C.; Jaeckle, K.; Klenke, R.; Aikin, A.; Murphy, R.; McCully, C.; Poplack, D.G. Intrathecal mafosfamide: A preclinical pharmacology and phase I trial. J. Clin. Oncol., 2005, 23(7), 1555-1563.
[http://dx.doi.org/10.1200/JCO.2005.06.053] [PMID: 15735131]
[54]
Salgia, S.; Fleming, G.F.; Lukas, R.V. Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin. J. Clin. Neurosci., 2014, 21(7), 1250-1251.
[http://dx.doi.org/10.1016/j.jocn.2013.09.018] [PMID: 24412296]
[55]
Tran, H.C.; Gardner, S.; Weiner, H.L.; Liebes, L.F.; Finlay, J.L. Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer. J. Oncol. Pharm. Pract., 2014, 20(3), 229-232.
[http://dx.doi.org/10.1177/1078155213494940] [PMID: 23929729]
[56]
Martens, J.; Venuturumilli, P.; Corbets, L.; Bestul, D. Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases. Acta Oncol., 2013, 52(1), 175-178.
[http://dx.doi.org/10.3109/0284186X.2012.689857] [PMID: 22655969]
[57]
Stemmler, H.J.; Mengele, K.; Schmitt, M.; Harbeck, N.; Laessig, D.; Herrmann, K.A.; Schaffer, P.; Heinemann, V. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: A case report. Anticancer Drugs, 2008, 19(8), 832-836.
[http://dx.doi.org/10.1097/CAD.0b013e32830b58b0] [PMID: 18690096]
[58]
Tobin, M.K.; Geraghty, J.R.; Engelhard, H.H.; Linninger, A.A. Intramedullary spinal cord tumors: A review of current and future treatment strategies. Neurosurg. Focus., 2015, 39(2), E14.
[59]
Balmaceda, C. Chemotherapy for intramedullary spinal cord tumors. J. Neurooncol., 2000, 47(3), 293-307.
[PMID: 11016745]
[60]
Hassall, T.; Mitchell, A.E.; Ashley, DMJN-o arboplatin chemotherapy for progressive intramedullary spinal cord low-grade gliomas in children: Three case studies and a review of the literature. Neuro. Oncol., 2001, 3(4), 251.
[61]
Bell, W.O.; Packer, R.J.; Seigel, K.R.; Rorke, L.B.; Sutton, L.N.; Bruce, D.A. Leptomeningeal spread of intramedullary spinal cord tumors: Report of three cases. J Neurosurg, 1988, 69(2), 295-300.
[http://dx.doi.org/10.3171/jns.1988.69.2.0295]
[62]
Xi, W.; Junling, L.; Jianping, X.; Boyan, Y.; Lei, Y.; Xiaoming, W. Efficacy and security of intrathecal with methotrexate in the treatment of meningeal carcinomatosis. Zhongguo Fei Ai Za Zhi, 2016, 19(5), 252-256.
[PMID: 27215452]
[63]
Pan, Z.; Yang, G.; He, H.; Zhao, G.; Yuan, T.; Li, Y.; Shi, W.; Gao, P.; Dong, L.; Li, Y. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study. Int. J. Cancer, 2016, 139(8), 1864-1872.
[http://dx.doi.org/10.1002/ijc.30214] [PMID: 27243238]
[64]
Salkade, P.R.; Teh, A.L. Methotrexate-induced acute toxic leukoencephalopathy. J. Cancer Res. Ther., 2012, 8(2), 292-296.
[65]
Cohen, IJ; Stark, B.; Kaplinsky, C.; Weitz, R.; Matz, S.; Lerman, P. Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: A case report and analysis of the literature. Pediatr. Hematol. Oncol., 1990, 7(1), 79-87.
[http://dx.doi.org/10.3109/08880019009034321]
[66]
Jaeckle, K.A.; Phuphanich, S.; Bent, M.J.; Aiken, R.; Batchelor, T.; Campbell, T.; Fulton, D.; Gilbert, M.; Heros, D.; Rogers, L.; O’Day, S.J.; Akerley, W.; Allen, J.; Baidas, S.; Gertler, S.Z.; Greenberg, H.S.; LaFollette, S.; Lesser, G.; Mason, W.; Recht, L.; Wong, E.; Chamberlain, M.C.; Cohn, A.; Glantz, M.J.; Gutheil, J.C.; Maria, B.; Moots, P.; New, P.; Russell, C.; Shapiro, W.; Swinnen, L.; Howell, S.B. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br. J. Cancer, 2001, 84(2), 157-163.
[http://dx.doi.org/10.1054/bjoc.2000.1574] [PMID: 11161370]
[67]
Glantz, M.J.; Jaeckle, K.A.; Chamberlain, M.C.; Phuphanich, S.; Recht, L.; Swinnen, L.J.; Maria, B.; LaFollette, S.; Schumann, G.B.; Cole, B.F.; Howell, S.B. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res., 1999, 5(11), 3394-3402.
[PMID: 10589750]
[68]
Grossman, S.A.; Krabak, M.J. Leptomeningeal carcinomatosis. Cancer Treat. Rev., 1999, 25(2), 103-119.
[http://dx.doi.org/10.1053/ctrv.1999.0119] [PMID: 10395835]
[69]
Scott, B.J.; van Vugt, V.A.; Rush, T.; Brown, T.; Chen, C.C.; Carter, B.S.; Schwab, R.; Fanta, P.; Helsten, T.; Bazhenova, L.; Parker, B.; Pingle, S.; Saria, M.G.; Brown, B.D.; Piccioni, D.E.; Kesari, S. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: A retrospective cohort study. J. Neurooncol., 2014, 119(2), 361-368.
[http://dx.doi.org/10.1007/s11060-014-1486-2] [PMID: 24942463]
[70]
Park, W.Y.; Kim, H.J.; Kim, K.; Bae, S.B.; Lee, N.; Lee, K.T.; Won, J.H.; Park, H.S.; Lee, S.C. Intrathecal trastuzumab treatment in patients with breast cancer and leptomeningeal carcinomatosis. Cancer Res. Treat., 2016, 48(2), 843-847.
[http://dx.doi.org/10.4143/crt.2014.234] [PMID: 25761487]
[71]
Comte, A.; Jdid, W.; Guilhaume, M.N.; Kriegel, I.; Piperno-Neumann, S.; Dieras, V.; Dorval, T.; Pierga, J.Y.; Cottu, P.H.; Mignot, L.; Bidard, F.C. Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. J. Neurooncol., 2013, 115(3), 445-452.
[http://dx.doi.org/10.1007/s11060-013-1244-x] [PMID: 24043602]
[72]
Ferguson, S.D.; Bindal, S.; Bassett, R.L., Jr; Haydu, L.E.; McCutcheon, I.E.; Heimberger, A.B.; Li, J.; O’Brien, B.J.; Guha-Thakurta, N.; Tetzlaff, M.T.; Tawbi, H.; Davies, M.A.; Glitza, I.C. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J. Neurooncol., 2019, 142(3), 499-509.
[http://dx.doi.org/10.1007/s11060-019-03121-2] [PMID: 30847840]
[73]
Raizer, J.J.; Rademaker, A.; Evens, A.M.; Rice, L.; Schwartz, M.; Chandler, J.P.; Getch, C.C.; Tellez, C.; Grimm, S.A. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer, 2012, 118(15), 3743-3748.
[http://dx.doi.org/10.1002/cncr.26709] [PMID: 22179954]
[74]
Archer, G.E.; Sampson, J.H.; McLendon, R.E.; Friedman, A.H.; Colvin, O.M.; Rose, M.; Sands, H.; McCullough, W.; Fuchs, H.E.; Bigner, D.D.; Friedman, H.S. Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. J. Neurooncol., 1999, 44(3), 233-241.
[http://dx.doi.org/10.1023/A:1006304424346] [PMID: 10720203]
[75]
Gururangan, S.; Petros, W.P.; Poussaint, T.Y.; Hancock, M.L.; Phillips, P.C.; Friedman, H.S.; Bomgaars, L.; Blaney, S.M.; Kun, L.E.; Boyett, J.M. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: A Pediatric Brain Tumor Consortium Study (PBTC-004). Clin. Cancer Res., 2006, 12(5), 1540-1546.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-2094] [PMID: 16533779]
[76]
Sampson, J.H.; Archer, G.E.; Villavicencio, A.T.; McLendon, R.E.; Friedman, A.H.; Bishop, W.R.; Bigner, D.D.; Friedman, H.S. Treatment of neoplastic meningitis with intrathecal temozolomide. Clin. Cancer Res., 1999, 5(5), 1183-1188.
[PMID: 10353755]
[77]
Mir, O.; Ropert, S.; Alexandre, J.; Lemare, F.; Goldwasser, F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann. Oncol., 2008, 19(11), 1978-1980.
[http://dx.doi.org/10.1093/annonc/mdn654] [PMID: 18845838]
[78]
Oliveira, M.; Braga, S.; Passos-Coelho, J.L.; Fonseca, R.; Oliveira, J. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res. Treat., 2011, 127(3), 841-844.
[http://dx.doi.org/10.1007/s10549-011-1417-2] [PMID: 21369716]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy